Efficacy of Chemotherapy Following Prior PARP-Inhibitor Treatment in Patients with Ovarian Cancer
Wirksamkeit einer Chemotherapie nach vorheriger PARP-Inhibitor-Behandlung bei Patientinnen mit Ovarialkarzinom
Cancer Research and Treatment · 15.01.2026 · 58 (1) · 292-299
DOI: 10.4143/crt.2024.1202 ↗Auf einen Blick
Bei rezidiviertem Ovarialkarzinom nach PARPi-Erhaltung zeigte sich unter Gemcitabin+Carboplatin ein längeres medianes PFS als unter anderen Platin-Regimen. Die Studie war retrospektiv.
Fragestellung
Wie wirksam ist die anschließende Therapie bei rezidivierendem Ovarialkarzinom nach PARPi-Behandlung, und unterscheiden sich die Regime im Outcome?
Methode
Multizentrische retrospektive Kohortenstudie mit Patientinnen mit Ovarialkarzinom von Januar 2012 bis Juni 2023; primärer Endpunkt PFS nach Rezidiv unter bzw. nach PARPi.
Ergebnisse
Von 318 Patientinnen rezidivierten 147/318 (46,2 %) nach PARPi-Erhaltung. Medianes PFS: Platin-Chemotherapie 7,3 Monate, Nicht-Platin-Chemotherapie 4,8 Monate, andere Therapien 11,4 Monate. Gemcitabin+Carboplatin: 10,1 vs. 6,6 Monate; p=0,019.
Schlussfolgerung der Autor:innen
In der anschließenden Chemotherapie bei rezidivierendem Ovarialkarzinom nach Platin-basierter Chemotherapie und PARPi zeigte Gemcitabin+Carboplatin ein Potenzial, das Rezidiv wirksamer zu verzögern als andere Therapien.
Kernaussagen
- 147/318 (46,2 %) rezidivierten nach PARPi-Erhaltung
- Medianes PFS: 7,3; 4,8; 11,4 Monate je Therapiegruppe
- Gemcitabin+Carboplatin: 10,1 vs. 6,6 Monate; p=0,019
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Research and Treatment, erschienen am 15.01.2026. Verfasst von Jung Chul Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Soonchunhyang University Bucheon Hospital, Bucheon, Korea. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Chong Kun Dang Pharmaceutical Corp., Soonchunhyang University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Considering the current lack of consensus on post–poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi) treatment strategies, this study aimed to evaluate the efficacy of subsequent therapy and compare the outcomes of regimes in patients with recurrent ovarian cancer after PARPi treatment.Materials and Methods This multi-center retrospective cohort study analyzed data on patients diagnosed with ovarian cancer between January 2012 and June 2023 who had previously used PARPi after first- to fourth-line platinum-based chemotherapy. The primary endpoint was progression-free survival (PFS), which was the interval between recurrence after using PARPi and subsequent recurrence in the case of recurrence.
Results
Of 318 patients, 147/318 (46.2%) recurred after the PARPi maintenance. Patients were categorized into groups based on subsequent therapy except non-treated (11/147, 7.5%): platinum-based chemotherapy (89/147, 60.5%), non-platinum-based chemotherapy (21/147, 14.3%), other treatments (26/147, 17.7%), and the median PFS (mPFS) for each group were 7.3, 4.8, and 11.4 months, respectively. Among the platinum-based chemotherapy group, the gemcitabine+carboplatin regimen demonstrated a longer mPFS (10.1 months) than the other regimens (6.6 months, p=0.019). In non-platinum-based chemotherapy, no statistically significant differences were observed among the regimens. And, in the other therapy group, where the proportion of patients with oligometastasis was as high as 88.5%, no significant differences were observed among the therapies, including other modalities.
Conclusion
In the subsequent chemotherapy of recurrent ovarian cancer after platinum-based chemotherapy and PARPi, the gemcitabine+carboplatin regimen demonstrated a potential to delay recurrence more effectively compared to other therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
- Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea.
- Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
- Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Förderung
- Chong Kun Dang Pharmaceutical Corp.
- Soonchunhyang University
Zitieren
APA
Kim, J. C., Park, J., Lee, Y. J., Nam, E. J., Kim, S. W., Kim, S. H., Kim, Y. T., Kim, S. I., Kim, J. W., Kim, B. G., & Lee, J. Y. (2026). Efficacy of Chemotherapy Following Prior PARP-Inhibitor Treatment in Patients with Ovarian Cancer. Cancer Research and Treatment, 58(1), 292-299. https://doi.org/10.4143/crt.2024.1202
Vancouver
Kim JC, Park J, Lee YJ, Nam EJ, Kim SW, Kim SH, et al. Efficacy of Chemotherapy Following Prior PARP-Inhibitor Treatment in Patients with Ovarian Cancer. Cancer Research and Treatment. 2026;58(1):292-299. doi:10.4143/crt.2024.1202
BibTeX
@article{Kim2026,
author = {Kim, Jung Chul and Park, Junsik and Lee, Yong Jae and Nam, Eun Ji and Kim, Sang Wun and Kim, Sung-Hoon and Kim, Young Tae and Kim, Se Ik and Kim, Jae-Weon and Kim, Byoung-Gie and Lee, Jung-Yun},
title = {Efficacy of Chemotherapy Following Prior PARP-Inhibitor Treatment in Patients with Ovarian Cancer},
journal = {Cancer Research and Treatment},
year = {2026},
volume = {58},
number = {1},
pages = {292--299},
doi = {10.4143/crt.2024.1202}
}
EUVIMED